Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors
- PMID: 24869933
- PMCID: PMC4435598
- DOI: 10.1038/mt.2014.89
Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors
Abstract
Gene therapy has not yet improved cystic fibrosis (CF) patient lung function in human trials, despite promising preclinical studies. In the human CF lung, inhaled gene vectors must penetrate the viscoelastic secretions coating the airways to reach target cells in the underlying epithelium. We investigated whether CF sputum acts as a barrier to leading adeno-associated virus (AAV) gene vectors, including AAV2, the only serotype tested in CF clinical trials, and AAV1, a leading candidate for future trials. Using multiple particle tracking, we found that sputum strongly impeded diffusion of AAV, regardless of serotype, by adhesive interactions and steric obstruction. Approximately 50% of AAV vectors diffused >1,000-fold more slowly in sputum than in water, with large patient-to-patient variation. We thus tested two strategies to improve AAV diffusion in sputum. We showed that an AAV2 mutant engineered to have reduced heparin binding diffused twice as fast as AAV2 on average, presumably because of reduced adhesion to sputum. We also discovered that the mucolytic N-acetylcysteine could markedly enhance AAV diffusion by altering the sputum microstructure. These studies underscore that sputum is a major barrier to CF gene delivery, and offer strategies for increasing AAV penetration through sputum to improve clinical outcomes.
Figures
Similar articles
-
Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients.PLoS One. 2011;6(5):e19919. doi: 10.1371/journal.pone.0019919. Epub 2011 May 27. PLoS One. 2011. PMID: 21637751 Free PMC article.
-
Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.Hum Gene Ther. 2006 Apr;17(4):440-7. doi: 10.1089/hum.2006.17.440. Hum Gene Ther. 2006. PMID: 16610931 Free PMC article.
-
Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells.Hum Gene Ther. 2008 Dec;19(12):1407-14. doi: 10.1089/hum.2008.117. Hum Gene Ther. 2008. PMID: 18778196 Free PMC article.
-
Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments.Expert Opin Biol Ther. 2017 Oct;17(10):1265-1273. doi: 10.1080/14712598.2017.1347630. Epub 2017 Jul 6. Expert Opin Biol Ther. 2017. PMID: 28657358 Free PMC article. Review.
-
Novel Lung Tropic Adeno-Associated Virus Capsids for Therapeutic Gene Delivery.Hum Gene Ther. 2020 Sep;31(17-18):996-1009. doi: 10.1089/hum.2020.169. Epub 2020 Sep 8. Hum Gene Ther. 2020. PMID: 32799685 Review.
Cited by
-
Advanced approaches to overcome biological barriers in respiratory and systemic routes of administration for enhanced nucleic acid delivery to the lung.Expert Opin Drug Deliv. 2023 Jul-Dec;20(11):1531-1552. doi: 10.1080/17425247.2023.2282535. Epub 2023 Dec 20. Expert Opin Drug Deliv. 2023. PMID: 37946533 Review.
-
Cervicovaginal mucus barrier properties during pregnancy are impacted by the vaginal microbiome.Front Cell Infect Microbiol. 2023 Mar 31;13:1015625. doi: 10.3389/fcimb.2023.1015625. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37065197 Free PMC article.
-
Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers.Int J Pharm. 2023 Mar 5;634:122661. doi: 10.1016/j.ijpharm.2023.122661. Epub 2023 Feb 1. Int J Pharm. 2023. PMID: 36736964 Free PMC article. Review.
-
An optimized protocol for assessment of sputum macrorheology in health and muco-obstructive lung disease.Front Physiol. 2022 Aug 5;13:912049. doi: 10.3389/fphys.2022.912049. eCollection 2022. Front Physiol. 2022. PMID: 35991170 Free PMC article.
-
Increasing stiffness promotes pulmonary retention of ligand-directed dexamethasone-loaded nanoparticle for enhanced acute lung inflammation therapy.Bioact Mater. 2022 Jun 28;20:539-547. doi: 10.1016/j.bioactmat.2022.06.016. eCollection 2023 Feb. Bioact Mater. 2022. PMID: 35846844 Free PMC article.
References
-
- O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891–1904. - PubMed
-
- Griesenbach U, Alton EW. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Pharm Des. 2012;18:642–662. - PubMed
-
- Johnson LG, Boyles SE, Wilson J, Boucher RC. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest. 1995;95:1377–1382. - PMC - PubMed
-
- Hyde SC, Gill DR, Higgins CF, Trezise AE, MacVinish LJ, Cuthbert AW, et al. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature. 1993;362:250–255. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
